BridgeMD
New treatment option for Septic Shock
Official title The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock
ClinicalTrials.gov ID: NCT06234592
What this study is testing
What is Angiotensin II?
Angiotensin II is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for septic shock.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Acute kidney injury (AKI) is a common complication of septic shock and together these conditions carry a high mortality risk. In septic patients who develop severe AKI renal cortical perfusion is deficient despite normal macrovascular organ blood flow.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Within 48 hours of intensive care admission
- Evidence of suspected or confirmed infection
- Sequential Organ Failure (SOFA) score increase of 2 or more (assuming a baseline of 0 if no previous measures)
- Requirement for norepinephrine infusion as the sole vasopressor agent in a dose of \>0.1mcg/kg/min
- Lactate \>2mmol/L at any stage prior to randomisation
You likely can't join if
- Known intolerance to Sonovue™ contrast medium, vasopressin or angiotensin II
- Patients receiving other vasoactive drugs in addition to norepinephrine
- Patients with known chronic kidney disease (CKD) stage 4 or 5 (baseline glomerular filtration rate (GFR) \<30mls/min)
- Patients receiving extra corporal membrane oxygenation (ECMO)
- Patients with acute occlusive coronary syndromes requiring intervention
- Patients with mesenteric ischaemia
See the full eligibility criteria
- Within 48 hours of intensive care admission
- Evidence of suspected or confirmed infection
- Sequential Organ Failure (SOFA) score increase of 2 or more (assuming a baseline of 0 if no previous measures)
- Requirement for norepinephrine infusion as the sole vasopressor agent in a dose of \>0.1mcg/kg/min
- Lactate \>2mmol/L at any stage prior to randomisation
- Known intolerance to Sonovue™ contrast medium, vasopressin or angiotensin II
- Patients receiving other vasoactive drugs in addition to norepinephrine
- Patients with known chronic kidney disease (CKD) stage 4 or 5 (baseline glomerular filtration rate (GFR) \<30mls/min)
- Patients receiving extra corporal membrane oxygenation (ECMO)
- Patients with acute occlusive coronary syndromes requiring intervention
- Patients with mesenteric ischaemia
- Patients with a history or presence of aortic dissection or abdominal aortic aneurysm
- Patients with Raynaud's syndrome or acute vaso-occlusive conditions
- Pregnancy
The study team makes the final eligibility decision.
Where it's taking place
- London, United Kingdom
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include London, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.